Point72 Asset Management
ACIU icon

Point72 Asset Management’s AC Immune ACIU Stock Holding History

Point72 Asset Management’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$806K Buy
293,200
+265,300
+951% +$824K ﹤0.01% 2886
2025
Q4 		$87.6K Buy
+27,900
New +$88K ﹤0.01% 3752

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Point72 Asset Management's ACIU Position: Q1 2026 in Review

Point72 Asset Management sold out of AC Immune (ACIU) in Q1 2026, closing a stake of 384,845 shares — an estimated $1.2M sold.

Point72 Asset Management first reported a position in ACIU in Q3 2016 and held it in 4 quarters. The position peaked at $2.99M in Q2 2021. 46 funds tracked by Wall St. Rank hold ACIU as of Q1 2026.

  • Point72 Asset Management reported no remaining AC Immune position as of Q1 2026 after selling out during the quarter.
  • Point72 Asset Management sold 384,845 AC Immune shares in Q1 2026, an estimated $1.2M.
  • Point72 Asset Management first reported a position in AC Immune in Q3 2016 and held it in 4 quarters.
  • Point72 Asset Management's AC Immune position peaked at $2.99M in Q2 2021.
  • 46 funds tracked by Wall St. Rank held AC Immune as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.